Fessler Samantha N, Liu Li, Chang Yung, Johnston Carol S
College of Health Solutions, Arizona State University, Tempe, Arizona, USA.
Biodesign Institute, Arizona State University, Tempe, Arizona, USA.
Obes Facts. 2024;17(6):652-657. doi: 10.1159/000540343. Epub 2024 Aug 8.
Obesity has arisen as a prominent risk factor for COVID-19 severity and long COVID, potentially owed in part to the obesity-induced proinflammatory state. This study aimed to examine relationships among circulating inflammatory biomarkers and body mass index in nonhospitalized adults recently diagnosed with COVID-19.
This analysis included participants who completed a randomized placebo-controlled trial conducted in October 2020-March 2021. Participants (19-53 years) were unvaccinated and enrolled following COVID-19 diagnosis as allowed by CDC return-to-work guidance. Anthropometrics and biomarkers were assessed at study baseline and week four. We examined the associations between body mass index (BMI) and inflammatory biomarkers via multiple regression models.
At study baseline (i.e., the point of enrollment following COVID-19 diagnosis) across all participants (N = 60), a higher BMI was associated with elevations in several inflammatory biomarkers including IL-6 (β = 7.63, 95% CI = 3.54, 11.89, p = 0.0004), ferritin (β = 6.31, 95% CI = 1.97, 10.83, p = 0.0047), high sensitivity C-reactive protein (β = 13.1, 95% CI = 8.03, 18.42, p = < 0.0001), tumor necrosis factor-α (β = 3.23, 95% CI = 0.91, 5.60, p = 0.0069), IL-12p40 (β = 3.69, 95% CI = 0.93, 6.52, p = 0.0094), IL-13 (β = 5.11, 95% CI = 1.00, 9.40, p = 0.0154), and IL-1Ra (β = 7.57, 95% CI = 3.61, 11.70, p = 0.0003). In control group participants (n = 30) after 4 weeks, a higher BMI was associated with elevations in IL-4 (β = 17.8, 95% CI = 0.84, 37.6, p = 0.0397) and sP-selectin (β = 1.16, 95% CI = 0.22, 2.11, p = 0.0182), controlling for baseline and covariates.
Here, BMI was positively associated with circulating biomarkers of platelet activation and inflammation in adults recently diagnosed with COVID-19 after 4 weeks. The shift in post-acute COVID-19 inflammatory biomarkers associated with an increasing BMI noted here shares similarities to biomarkers of LC reported in the literature.
肥胖已成为新冠病毒疾病(COVID-19)严重程度和新冠后综合征(long COVID)的一个突出风险因素,这可能部分归因于肥胖引发的促炎状态。本研究旨在探讨近期诊断为COVID-19的非住院成年人中循环炎症生物标志物与体重指数之间的关系。
本分析纳入了在2020年10月至2021年3月期间完成一项随机安慰剂对照试验的参与者。参与者年龄在19至53岁之间,未接种疫苗,根据美国疾病控制与预防中心(CDC)的复工指南,在确诊COVID-19后入组。在研究基线和第4周时评估人体测量指标和生物标志物。我们通过多元回归模型研究体重指数(BMI)与炎症生物标志物之间的关联。
在研究基线时(即COVID-19诊断后的入组时间点),所有参与者(N = 60)中,较高的BMI与多种炎症生物标志物升高相关,包括白细胞介素-6(IL-6)(β = 7.63,95%置信区间[CI] = 3.54,11.89,p = 0.0004)、铁蛋白(β = 6.31,95% CI = 1.97,10.83,p = 0.0047)、高敏C反应蛋白(β = 13.1,95% CI = 8.03,18.42,p = < 0.0001)、肿瘤坏死因子-α(β = 3.23,95% CI = 0.91,5.60,p = 0.0069)、IL-12p40(β = 3.69,95% CI = 0.93,6.52,p = 0.0094)、IL-13(β = 5.11,95% CI = 1.00,9.40,p = 0.0154)和IL-1受体拮抗剂(IL-1Ra)(β = 7.57,95% CI = 3.61,11.70,p = 0.0003)。在第4周后的对照组参与者(n = 30)中,在控制基线和协变量后,较高的BMI与IL-4(β = 17.8,95% CI = 0.84,37.6,p = 0.0397)和可溶性P选择素(sP-selectin)(β = 1.16,95% CI = 0.22,2.11,p = 0.0182)升高相关。
在此,BMI与近期诊断为COVID-19的成年人4周后循环中的血小板活化和炎症生物标志物呈正相关。此处观察到的与BMI增加相关的急性COVID-19后炎症生物标志物的变化与文献中报道的新冠后综合征(LC)的生物标志物相似。